CEVEC is Transforming Vaccine Development starting with Zika
CEVEC Pharmaceuticals recently partnered up with NewLink Genetics to use its CAP technology for the development of new vaccines against the Zika virus. We had the opportunity to ask CEVECs CSO a few questions about how their technology can transform vaccine development.
Labiotech.eu, February 20, 2017
CEVEC Pharmaceuticals is developing high-quality platforms for the efficient and safe production of glycosylated proteins, viral vaccines and gene therapy vectors. Their CAP technology consists of robust cell-lines which are extensively documented and able to be easily scaled up for cost-efficient production processes. With their virus-producing cell lines CAP-GT, CEVEC is making significant contributions to the development of safer vectors for gene therapy. Now they are planning to enter the vaccine market.
CEVEC licenses CAP® technologies for the development and commercialization of vaccines against Zika Virus infections
Agreement marks an important step in establishing CAP® technologies as the new global industrial standard for viral vector and vaccine development
Cologne, Germany, February 09, 2017
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with NewLink Genetics (NASDAQ:NLNK) for use of its proprietary CAP®GT and CAP®Go cell lines in the development and commercialization of products for the treatment and prophylaxis of Zika virus infections.
Meet the CEO making the Next Generation of Gene Therapies Possible
Labiotech.eu., November 16, 2016
How do you solve a problem like lentiviral vector infections? CEVEC has done it. We sat down with the CEO, Frank Ubags, to talk about his company’s success.
The last few decades have not been kind to gene therapy companies, but the field seems to be on the edge of a renaissance with adenoviral vectors as a means of delivery. CEVEC’s contribution is a platform that includes two technologies, CAP-Go for the tailor-made production of previously inaccessible recombinant proteins and CAP-GT for industrial scale production of lentiviral, adenoviral and AAV gene therapy vectors.
CEVEC is Revolutionizing
Industrial Protein & Viral Vector Production
Labiotech.eu., November 3, 2016
CEVEC just filed a Biologics Master File (BB-MF) to the FDA for its CAP technology, which outperforms all current standards in the production of gene therapy vectors and glycosylated human proteins.
CEVEC submits Biologics Master File (BB-MF) for CAP® Technology to the U.S. FDA
- Submission represents an important step towards establishing CAP®GT and CAP®Go technologies as the new industrial standards for viral vaccines, commercial-scale gene therapy vectors and recombinant protein production.
- CEVEC’s CAP® technology licensees can reference BB-MF, simplifying and accelerating their regulatory approval process for a CAP®-derived product.
Cologne, Germany, October 27, 2016
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that is has submitted a Biologics Master File (BB-MF) for its human cell substrate CAP® to the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER).
This Technology Opens new Horizons for Protein Production
Labiotech.eu, October 19, 2016
Based in Cologne (Germany), Cevec focuses on human cell-based expression system for production of biological therapies. We’ve already covered their breakthroughs for safer gene therapy and the potential of CAP-GT for expression of viral vectors.
Besides CAP-GT, CEVEC has also developed a cell line that can produce complex glycosylated proteins. A good example of glycosylated protein is the therapeutic plasma protein. So far, these proteins have been isolated from donated human plasma by companies like Octapharma (a big company in Zurich’s Biotech ecosystem). With Cevec’s CAP-Go, recombinant plasma proteins can be produced for the first time.
Join CEVEC Pharmaceuticals GmbH at three upcoming Gene Therapy conferences:
Phacilitate’s Cell & Gene Therapy Europe
September 21-22, 2016, BERLIN, GERMANY
Listen to the presentation of CEVEC’s CSO Dr. Nicole Faust: “Case Study: CAP®GT, novel human suspension cell lines for scalable production of viral vectors” in Stream 1 on Wednesday, September 21 at 12:20 CET.
Visit CEVEC at booth # 6.
For more details about the meeting click here
Informa’s Cell & Gene Therapy Bioprocessing & Commercialization
October 5-7, 2016, BOSTON, USA
Visit CEVEC at booth # 1147.
For more details about the meeting click here
ESGCT/ISSCR Collaborative Congress 2016
October 18-21, 2016, FLORENCE, ITALY
Visit CEVEC at booth # 24.
For more details about the meeting click here
Cevec: “Our Special Cell Lines will help the next generation of Gene Therapy”
Labiotech.eu, September 1, 2016
Cevec could very well be the missing link between adenoviral vectors and approved gene therapies. LABIOTECH had a chat with the CSO of Cevec about what makes its technology great and how it’s ready for the future of gene therapy.
CEVEC further strengthens organization to drive industrialization and commercialization of CAP® technologies
- Life sciences industry veteran Bart Bergstein to join CEVEC’s Supervisory Board
- Two newly formed Scientific Advisory Boards for CEVEC’s CAP®GT and CAP®Go technologies will further drive industrialization
Cologne, Germany, June 29, 2016
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a strengthening of the Company reflective of its strategic progress.
German Biotech partners up in the US for scalable viral vector production in Gene Therapy
Labiotech.eu 07/06/2016 – Cevec is joining forces with US-based Paragon. The objective is to make Cevec’s scalable CAP® expression technology the industry standard for glycoproteins and viral vectors in gene therapies.
Based in Cologne (Germany), Cevec tackles with its human cell-based expression systems CAP®GT and CAP®Go two big challenges in Biotech manufacturing – industrial scale production of viral vectors and complex glycoproteins.
CAP®GT is a platform to produce viral vectors, such as lentivirus (LV) adenovirus (AV) and adeno-associated virus (AAV). These viral vectors are used to carry genetic information to the target cells in the patient’s body in gene therapy.
Cevec: Paragon als Partner
transkript.de/bk 06. Juni 2016 – Die Kölner Cevec Pharmaceuticals GmbH setzt auf das US-Unternehmen Paragon Bioservices um der eigenen CAP-Zelllinientechnologie in Nordamerika zum Durchbruch zu verhelfen.
Es ist eine umfassende Kooperation, die Anfang Juni zwischen dem Technologieentwickler Cevec Pharmaceuticals und dem Lohnhersteller Paragon Bioservices vereinbart wurde. Demnach werden die US-Amerikaner der bevorzugte Partner im Bereich der Auftragsentwicklung und -fertigung in Nordamerika. „Die Vereinbarung ist ein wichtiger nächster Schritt in der Umsetzung unserer Strategie und bildet den Ausgangspunkt für den Roll-out unserer CAP-Technologien in den nordamerikanischen Märkten“, sagte Cevec-Geschäftsführer Frank Ubags.
CEVEC and Paragon Bioservices enter into comprehensive collaboration to roll out CAP® technologies in North America
- Agreement establishes Paragon as CEVEC’s preferred partner for contract development and manufacturing (CDMO) services in North America
- Companies will conduct coordinated marketing and business development activities to establish CEVEC’s CAP® technologies as a new standard for gene therapy vector production
- Collaboration includes developing a scalable clinical production process for AAV-based gene therapy vectors based on the CAP®GT platform
Cologne, Germany and Baltimore, MD, USA, June 6th, 2016
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors and Paragon Bioservices, Inc., a leader in the manufacturing of biopharmaceuticals and vaccines, today announced that the companies signed a collaboration and license agreement to jointly establish CEVEC’s proprietary CAP® technologies as a new industry standard for the scalable production of viral gene therapy vectors in North America.
CEVEC’s CAP®GT sets a new standard through RCA-free production of adenoviral vectors for gene therapy applications
- CAP®GT technology for fully scalable industrial adenoviral vector production with proven absence of replication-competent adenovirus (RCA)
- CAP®GT technology is underway to replace HEK293 as current production host for adenoviral vectors
Cologne, Germany, May 10, 2016
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company’s proprietary cell-expression system, CAP®GT, has delivered the production of safe adenoviral (AV) gene therapy vectors with the proven absence of RCAs.
CEVEC trifft mit Gentherapie-Vektoren ins Schwarze
Interview mit www.transkript.de – 3/2016
Zahlreiche neue Partnerschaften konnte der Expressionsspezialist Cevec Pharmaceuticals für seine CAP-Zelllinien abschließen. Der Geschäftsführer Frank Ubags erläutert im Gespräch mit transkript die ergeizigen Pläne des Kölner Unternehmens.
CEVEC intensifies its marketing activities, presenting at various renowned scientific conferences in Europe and the US
Cologne, Germany, February 22, 2016
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will present at the following renowned international scientific cell culture and gene therapy conferences in Europe and the US to promote the unique and superior features of its proprietary platform technologies CAP®Go and CAP®GT to industrial players in biopharmaceutical and gene therapy applications.
CEVEC and Beckman Research Institute of City of Hope enter into a cooperation and license agreement on CEVEC’s proprietary CAP®GT technology
- CEVEC’s CAP®GT technology enables fully scalable lentiviral and RCA (replication competent adenovirus)-free adenoviral vector production
- Further step to establish CEVEC’s CAP®GT technology as the industrial standard for the production of lentiviral and adenoviral gene therapy vectors
Cologne, Germany, January 20, 2016
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a collaboration agreement with Beckman Research Institute of City of Hope (“Beckman Research Institute”) on CEVEC’s proprietary CAP®GT technology.
Join CEVEC Pharmaceuticals GmbH at Phacilitate Cell & Gene Therapy World 2016
January 25-27 in Washington D.C.
Meet the CEVEC Team at booth 107 and listen to the talk of Dr. Nicole Faust, Chief Scientific Officer at CEVEC:
“CAP-GT, Novel Human Suspension Cell Lines for Scalable Production of Viral Vectors”
on January 25th, 05:05 pm in Focus Session 2
• Scalable production of gene therapy vectors
• Fully characterized cell line optimized for high density growth and viral vector production
• Safe production of Adenoviral vectors
Novel Method for Glycoprotein Expression
GEN Bioprocessing Tutorial – November 1 Issue, 2015
Silke Wissing, Ph.D., Jens Wölfel, Ph.D., Helmut Kewes, Christian Niehus, Corinna Bialek, Sabine Hertel, and Nicole Faust, Ph.D.
Utilizing CAP-Go Cells for Optimizing Serum Half-Life and Glycosylation Profile
Science Only Accounts For Fifty Percent of a Project’s Success: An interview with Frank Ubags
bio-live.de – November 6, 2015
Interview conducted by Rieke Winter
CEVEC Pharmaceutical’s CEO Frank Ubags on the Technologies Developed by His Company, the Need for Sound Project Management and Dealing With Ethical Conundrums
CEVEC and BioLamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies
- CEVEC adds laminins as CAP®Go application in the field of ex vivo cell culture products for cell therapies
- CEVEC’s CAP®Go to displace HEK293 and CHO cell lines in GMP manufacturing
- BioLamina to further grow its leading high quality ex vivo cell culture laminin product portfolio
- First commercial CAP®Go-derived laminin, LN-521, expected to be globally available in 2016
Cologne, Germany and Stockholm, Sweden, October 28th, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, and BioLamina AB, a leading manufacturer of high quality products for primary cell culture, announced today a strategic collaboration …
Scalable production of gene therapy vectors: an interview with Frank Ubags
news-medical.net – October 26, 2015
Interview conducted by April Cashin-Garbutt, MA (Cantab)
Insights from industry Frank Ubags CEO, CEVEC Pharmaceuticals GmbH Gene therapy involves introducing genetic material into cells to replace missing or malfunctioning genes or to add a gene to express a beneficial protein in order to treat certain diseases, such as cancer or inherited disorders. …
CEVEC strengthens team to execute rapid growth strategy
- Dr. Nico Scheer appointed as Vice President Business Development Glycoproteins
- Dr. Hartmut Tintrup appointed as Vice President Business Development Gene Therapy and Viruses
- Headcount increased by 40% since May 2015
Cologne, Germany, October 14, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the expansion and reorganization of its management team.
CEVEC and Généthon sign a collaboration agreement to develop lentiviral vector packaging cell lines based on CEVEC’s proprietary CAP®GT technology
- Agreement enables fully scalable, industrial lentivirus vector production
- Collaboration represents an important step in the roll-out of CEVEC’s strategy to position CAP®GT technology as the industrial standard for the production of lentiviral vectors for commercial gene therapy applications
Cologne, Germany, September 17, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a collaboration agreement with Généthon (Evry, France) for the development and exploitation of lentivirus packaging cell lines based on CEVEC’s proprietary CAP®GT technology.
CEVEC introduces CAP®GT cell-expression system for scalable
viral gene therapy vector production
Cologne, Germany, September 7, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP®GT for the fully scalable production of gene therapy vectors, based on the Company’s proprietary CAP® technology.
CEVEC raises € 4.5 million in a financing round to commercialize its leading CAP® based technologies
- New and existing investors participated in this financing round
- CEVEC is setting new industry standards in glyco-optimized protein and gene therapy vector production with proprietary CAP®Go and CAP®GT technologies
Cologne, Germany, July 22, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the successful completion of a financing round of € 4.5 million. New investors included Investtodate GmbH, Frank Ubags, CEO, and Nicole Faust, CSO of CEVEC. Existing investors also participated in this financing. These included Peppermint VenturePartners GmbH, Creathor Venture Management GmbH, NRW.Bank, KfW Bank, G.A.T. Holding as well as a number of private individuals.
CEVEC’s CAP®Go derived recombinant placental human alkaline phosphatase shows superior results in a preclinical study
- New CAP®Go cell line for the production of glyco-optimized recombinant human alkaline phosphatase successfully established
- CAP®Go derived recombinant human alkaline phosphatase optimized to address therapeutic needs in chronic inflammatory indications and neurodegenerative diseases
Cologne, Germany, July 06, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins, today announced the results of a preclinical animal study in which its CAP®Go derived recombinant placental human alkaline phosphatase (PLAP) showed significantly prolonged serum-half-life.
CEVEC grants license to Biotest AG for production of tailor-made glycoproteins
Cologne, Germany, July 1, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), an expert for the production of glyco-optimized biopharmaceuticals, today announced that it has granted a license for its proprietary CAP®Go technology to Biotest AG for the development, production and commercialization of candidate molecules to treat the symptoms of hemophilia patients.
CEVEC INTRODUCES CAP®GO EXPRESSION SYSTEMS FOR SCALABLE PRODUCTION OF TAILOR-MADE GLYCOPROTEINS
Cologne, Germany, June 1, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), a global solution and service provider for the production of biopharmaceuticals based on a unique human cellular expression system, today announced the introduction of the technology platform CAP®Go for the fully scalable production of tailor-made glycosylated recombinant proteins, based on the Company’s proprietary CAP® Technology.
CEVEC ANNOUNCES APPOINTMENT OF
LIFE SIENCES INDUSTRY EXPERT FRANK UBAGS
AS CHIEF EXECUTIVE OFFICER
Cologne, Germany, April 17, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), the provider of novel human cell expression systems, today announced the appointment of Frank Ubags as Chief Executive Officer starting immediately. He replaces Wolfgang Kintzel who is moving into the investor side of the life sciences industry. He will continue to serve as an advisor to CEVEC.
CEVEC: CAP® DERIVED RECOMBINANT C1 INHIBITOR MATCHES BERINERT® IN ANIMAL STUDY
Cologne, Germany, February 2, 2015
CEVEC Pharmaceuticals, the developer and licensor of the CAP® Technology, today announced a major milestone regarding its recombinant human CAP® cell derived C1 Esterase Inhibitor (C1Inh).
CEVEC´s CAP derived C1 Inhibitor material showed in a pivotal pharmacokinetic rat study a serum half life matching one of the two currently available, plasma derived treatments, Berinert®. All other known versions of recombinant C1 Inh, including e.g. Ruconest® from transgenic rabbits, displayed so far a significantly shorter half life than …
CEVEC INTRODUCES CMO SERVICES
FOR THE cGMP MANUFACTURING OF CAP-BASED
Cologne, Germany, September 23, 2014
CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology today announced the extension of its CAP Technology business portfolio by offering cGMP compliant Contract Manufacturing Services.
CAP-derived clinical materials comprising recombinant proteins, vaccines and gene therapy vectors are now directly available from CEVEC to support Phase I+II clinical studies.